Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-06
1998-09-01
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546122, 546123, A61K 31435, C07D47104
Patent
active
058011838
ABSTRACT:
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia, and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment or prevention a substituted or unsubstituted pyridine and pyridine (N-oxide) analogs of 4-hydroxydihydroquinolones, tetrahydroquinoline-trione-oximes and quinoxalones, tautomers and pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
REFERENCES:
patent: 4103257 (1978-07-01), Hammond
patent: 4128649 (1978-12-01), Hardtmann
patent: 4215123 (1980-07-01), Scotese
patent: 5055465 (1991-10-01), Davey
patent: 5196421 (1993-03-01), McQuaid et al.
patent: 5252584 (1993-10-01), Carling et al.
patent: 5268378 (1993-12-01), Baker et al.
patent: 5283244 (1994-02-01), Sakamoto et al.
patent: 5424311 (1995-06-01), Billhardt-Troughton et al.
Bigge, C.F., "Structural Requirements for the Development of Potent N-Methly-D-Aspartic Acid (NMDA) Receptor Antagonists", Biochem. Pharmacol. 45(8):1547-1561 (Apr. 22, 1993).
Bigge, C.F. and Boxer, P.A., "Neuronal Cell Death and Strategies for Neuroprotection", in: Annual Reports in Medicinal Chemistry, vol. 29, McCall (Ed.), San Diego: Academic Press, Inc., pp. 13-22 (Aug. 24, 1994).
Carling, R.W. et al., "3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory Amino Acid Antagonists Acting at Glycine-Site NMDA and (RS)-.alpha.-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Recepetors", J. Med. Chem. 36:3397-3408 (1993).
Gray, N.M. et al., "Novel Indole-2-carboxylates as Ligands for the Strychnine-Insensitive N-Methyl-D-aspartate-Linked Glycine Receptor", J. Med. Chem. 34:1283-1292 (1991).
Kaye, I.A., "Some Substituted Pyrido(2,3)pyrazines", J. Med. Chem. 7:240-241 (Mar., 1964).
Kessler, M. et al., "A Glycine Site Associated with N-Methyl-D-Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists", J. Neurochem. 52(4):1319-1328 (1989).
Kulagowski et al., "3'-(Arylmethyl)- and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor", J. Med. Chem. 37:1402-1405 (May 13, 1994).
Leeson, P.D. et al., "Amino Acid Bioisosteres: Design of 2-Quinoline Derivatives as Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists", Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
Leeson, P.D., "Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists", in: Drug Design for Neuroscience, Kozikowski, A.P. (Ed.), New York: Raven Press, Ltd., pp. 339-381 (1993).
Leeson, P.D. and Iversen, L.L., "The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential", J. Med. Chem. 37(24):4053-4067 (Nov. 25, 1994).
Lipton, S.A., "Prospects for Clinically Tolerated NMDA Antagonists: Open-Channel Blockers and Alternative Redox States of Nitric Oxide", Trends in Neurosci. 16(12):527-532 (Dec., 1993).
Lipton, S.A. and Rosenberg, P.A., "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders", New Engl. J. Med. 330(9):613-622 (Mar. 3, 1994).
McQuaid, L.A. et al., "Synthesis and Excitatory Amino Acid Pharmacology of a Series of Heterocyclic-Fused Quinoxalinones and Quinazolinones", J. Med. Chem. 35:3319-3324 (1992).
Monn, J.A. and Schoepp, D.D., "Recent Progress in Excitatory Amino Acid Research", in: Annual Reports in Medicinal Chemistry, vol. 29, McCall (Ed.), San Diego: Academic Press, Inc., pp. 53-64 (Aug. 24, 1994).
Rowley, M., "3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically Active Anticonvulsants Acting by Antagonism as the Glycine Site of the N-Methyl-D-Aspartate Receptor Complex", J. Med. Chem. 36:3386-3396 (1993).
Sakamoto, S. et al., "Preparation of Diketopiperazines as Glutamate Receptor Antagonists", Chem. Abstr. 117:695, Abstract No. 251367d (1992).
Winterfeld, K. and Wildersohn, M., "2,3-Dichlor-und 2,3,7-Trichlor-5-aza-chinoxalin", Archiv der Pharmazie 303(1):44-48 (1970).
Czuba W, Kowalska T, Kowalski P. Pol. J. Chem. 52(12), 2369-76. (abstract), 1978.
Santilli AA, Scotese AC, Bauer RF, Bell SC. J. med. Chem. 30(12), 2270-7. (abstract), 1987.
Mohamed EA, Abdel-Rahman RM, El-Gendy Z, Ismail MM. An.Quim. 89(2), 246-53. (abstract), 1993.
Soliman AY, Bakeer HM. Chin. J. Chem. 9(5), 461-6. (abstract), 1991.
Cai Sui Xiong
Keana John F. W.
Navratil James M.
Zhou Zhang-Lin
Cocensys Inc.
Huang Evelyn
Ivy C. Warren
State of Oregon Acting by and Through the Oregon State Board of
LandOfFree
Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-270602